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Abstract Since germline mutations in the PALB2 (Part-
ner and Localizer of BRCA2) gene have been identiﬁed as
breast cancer (BC) susceptibility alleles, the geographical
spread and risks associated with PALB2 mutations are
subject of intense investigation. Patients with bilateral
breast cancer constitute a valuable group for genetic stud-
ies. We have thus scanned the whole coding region of
PALB2 in a total of 203 German or Russian bilateral breast
cancer patients using an approach based on high-resolution
melting analysis and direct sequencing of genomic DNA
samples. Truncating PALB2 mutations were identiﬁed in
4/203 (2%) breast cancer patients with bilateral disease.
The two nonsense mutations, p.E545X and p.Q921X, have
not been previously described whereas the two other
mutations, p.R414X and c.509_510delGA, are recurrent.
Our results indicate that PALB2 germline mutations
account for a small, but not negligible, proportion of
bilateral breast carcinomas in German and Russian
populations.
Keywords PALB2  Breast cancer  High-resolution
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Introduction
Breast cancer (BC) has an inherited component, and the
high-penetrance breast cancer predisposing genes, BRCA1
and BRCA2, account for up to 10–30% of familial breast
cancer clustering [1–3]. Other relevant genes, such as
CHEK2, NBS1, PALB2, BRIP1, etc., also contribute to
hereditary breast cancer, although their impact appears to
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DOI 10.1007/s10549-010-1290-4be somewhat more population-speciﬁc [4]. The PALB2
(Partner and Localizer of BRCA2) gene is located on
chromosome 16p12.2 and encodes for a protein involved in
BRCA2-related pathways [5]. Its biallelic inactivation
results in Fanconi anemia, while the presence of a germline
mutation in the heterozygous state is associated with
increased risk of breast, pancreatic, and possibly some
other cancers (Table 1 and references therein). The geo-
graphical spread of PALB2 mutations has not been com-
prehensively analyzed yet, and several recent studies have
failed to identify any PALB2 mutations in breast cancer
series from their population [24–27]. The search for breast
cancer predisposing mutations is considered to be partic-
ularly effective in patient series with a pronounced family
history of the disease. However, the collection of multi-
case breast cancer families can be complicated in countries
with low birth rate and/or recent historical turbulences and/
or lack of comprehensive registration of (familial) cancer
cases. Others and we have suggested that patients with
bilateral occurrence of breast cancer constitute a valuable
group for genetic studies [28–31]. It has been calculated
that the bilateral occurrence of breast cancer can be con-
sidered an equivalent of the presence of two affected ﬁrst-
degree relatives [28].
We have previously employed population-speciﬁc series
of patients with bilateral breast cancer to study the distri-
bution of germline mutations in BRCA1, BRCA2,o r
CHEK2 [30, 32]. Here we report on the identiﬁcation of
PALB2 mutations in patients with bilateral breast cancer
from Germany and Russia.
Patients and methods
The German case series consisted of 158 patients from
Lower Saxony (Northern Germany) with bilateral breast
cancer who had been recruited at the time they received
radiotherapy either at Hannover Medical School during the
years 1996–2005 (n = 112), or at the University Medical
Center Go ¨ttingen during the years 2007–2009 (n = 46). 70
(44%) patients had synchronous bilateral BC (mean age:
59 years; age range 29–83 years) and 88 (56%) patients
had metachronous disease (mean age for the ﬁrst tumor:
51 years; age range 27–72 years; mean age for the second
tumor: 60 years; age range 31–82 years). Five (3%)
women were diagnosed with her ﬁrst primary below age
30 years, 16 (10%) between 30 and 39 years, 30 (19%)
between 40 and 49 years, and 107 (68%) at the age of
50 years or above. Family history revealed at least one
ﬁrst-degree relative with breast cancer in 29 (18%) of the
cases, and a second-degree family history of breast cancer
in 14 (9%) additional patients. Two women also had a
personal history of ovarian cancer. Pathogenic BRCA1 or
BRCA2 mutations were known in ten of the German
patients (6%); these patients were left within the study.
The Russian bilateral breast cancer patients were rep-
resented by 45 BRCA1/BRCA2 mutation-negative women,
who underwent treatment in the N.N. Petrov Institute of
Oncology (St.-Petersburg) in the years 1999–2009. 16
(36%) patients had synchronous bilateral BC (mean age:
53 years; age range 30–77 years) and 29 (64%) patients
had the metachronous disease (mean age for the ﬁrst tumor:
47 years; age range 25–77 years; mean age for the second
tumor: 58 years; age range: 28–86 years). Age at ﬁrst BC
onset was below 30 years in two (4%) women, between 30
and 39 years in ﬁve (11%) cases, between 40 and 49 years
in 17 (38%) patients, and 50 years or above in 21 (47%)
females. 13 (29%) of the women reported a ﬁrst-degree
family history of the disease, and seven (16%) additional
patients had second-degree relatives affected by BC.
PCR ampliﬁcations were set up in the presence of the
EvaGreen dye (BioBudget, Krefeld, Germany), and high-
resolution melting analysis was performed on the Rotor-
Gene 6000 real-time PCR machine (Corbett Research,
Mortlake, Australia). Primer sequences are described in the
Supplementary Table 1. Melting proﬁles were evaluated
using the Melt Curve Analysis tool of the Rotor-Gene 6000
Series Software Version 1.7. All samples with suspicious
melting behavior were then subjected to direct sequencing
to identify the underlying substitution. The three common
PALB2 polymorphisms, p.Q559R, p.E672Q, and p.G998E,
were conﬁrmed by allele-speciﬁc TaqMan assays on a
7500FAST Sequence Detection System platform.
The population frequency and the location of missense
substitutions were assessed using the SNP database of the
NCBI Genbank (http://www.ncbi.nlm.nih.gov/snp)a n dU n i -
protKB (http://www.uniprot.org/uniprot/). Bioinformatic
analyses of missense substitutions were performed using
SIFT (http://sift.jcvi.org/sift-bin/SIFT_BLink_submit.html)
or PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/, with
Q86YC2 as the protein identiﬁer and in the HumDiv trained
mode), which predict pathogenicity on the basis of evolu-
tionary and structural calculations.
The project has been approved by the Ethical Boards of
all participating research centers which contributed DNA
samples to the study.
Results and discussion
All portions of the PALB2 coding region were successfully
analyzed by high-resolution melting (Supplementary
Fig. 1). Direct sequencing of samples with suspicious
melting proﬁles revealed four truncating and several mis-
sense mutations. A list of the identiﬁed nucleotide sequence
changes is provided in Table 2.
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123Table 1 Survey of inactivating PALB2 mutations in patients with cancer or Fanconi anemia
Study Country/ethnicity Patients PALB2 mutations Founder effect
Breast cancer
Erkko et al.
[6]
Finland 113 Familial, BRCA1/2
negative
1592delT (L531fs): 3 19/947 (2%) familial BC,
8/1274 (0.6%) sporadic
BC, 2/1079 (0.2%)
controls [7]
Rahman et al.
[8]
UK 923 Familial, BRCA1/2
negative
2386G[T (G796X): 1; 2982insT (A995fs): 1;
3113G[A (W1038X): 2; 3116delA (N1039fs): 3;
3549C[G (Y1183X): 3
Tischkowitz
et al. [9]
Canada
(Ashkenazi
Jews, French
Canadian, other)
68 Familial, BRCA1/2
negative
229delT (C77fs)
Foulkes et al.
[10]
Canada (French
Canadian)
50 Young-onset
(\50 years) or familial
2323C[T (Q775X) 2/356 (0.6%) young-onset BC
Cao et al. [11] China 360 Young-onset
(\35 years) or familial
751C[T (Q251X): 2; 1050_1051delAAinsTCT
(Q350fs): 1
Garcia et al.
[12]
Spain 95 Familial, BRCA1/2
negative
1056_1057delGA (K353fsX7)
Sluiter et al.
[13]
South Africa
(whites)
48 Young-onset
(29–45 years)
697delG (V233fs)
Adank et al.
[14]
The Netherlands 110 Cancer families with
BRCA2-like clinical
features, BRCA1/2
negative
509_510delGA (R170fs)
Balia et al. [15] Italy 95 Familial, BRCA1/2
negative
1317delG (G439fs)
Ding YC et al.
[16]
USA 97 Male, BRCA2
negative
3549C[A (Y1183X)
Papi et al. [17] Italy 132 Familial, BRCA1/2
negative
2257C[T (R753X)
Present study Germany 158 Bilateral 509_510delGA (R170fs), 1633G[T (E545X)
Present study Russia 45 Bilateral, BRCA1/2
negative
1240C[T (R414X), 2761C[T (Q921X)
Pancreatic cancer
Jones et al. [18] USA 97 Familial 172_175delTTGT (S58fs); IVS5-1G[T; 3116delA
(N1039fs); 3256C[T (R1086X)
Tischkowitz
et al. [19]
Canada 254 Familial and
sporadic
Deletion of the exons 12 and 13
Slater et al.
[20]
Europe 81 Familial 1240C[T (R414X), 508_509delAG (R170fs),
3116delA (N1039fs)
Ovarian cancer
Dansonka-
Mieszkowska
et al. [21]
Poland 70 509_510delGA (R170fs) 2/339 (0.6%) ovarian cancer
cases, 4/648 (0.6%) familial
BC, 1/1310 (0.08%) controls
Fanconi anemia
Reid et al. [22] Various 82, negative for
mutations in other
known FA genes
Biallelic mutations: 395delT (V132fs)/3113?5G[C
(r.2835_3113del279/A946fs); 757_758delCT
(L253fs)/3294_3298delGACGA (K1098fs);
2257C[T (R753X)/3549C[A (Y1183X);
2393_2394insCT (T799fs)/3350?4A[G
(r.3350insGCAG/F1118fs); 2521delA (T841fs)/
3323delA (Y1108fs); 2962C[T (Q988X)/
3549C[G (Y1183X); 3116delA (N1039fs)/
3549C[G (Y1183X)
Xia et al. [23] Case report Biallelic mutation: Y551X/deletion of the exons 2–6
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patients led to the identiﬁcation of two (1.3%) truncating
mutations, both located in exon 4 of the PALB2 gene. The
c.1633G[T allele (p.E545X) has not been described in
prior literature, while the c.509_510delGA (p.R170fs)
mutation appears to be recurrent in Poland, a neighboring
country of both Germany and Russia [21]. The patient with
the novel PALB2 mutation, p.E545X, was diagnosed at the
age of 83 years as having bilateral invasive ductal carci-
noma (IDC) with estrogen and progesterone receptor neg-
ative tumors (T2N1M0 and T2N0M0). She did not have an
apparent family history of breast cancer, but reportedly her
maternal grandmother suffered from stomach cancer and
her sister died at the age of 67 from a cancer of unknown
origin. The second German PALB2 mutation carrier, het-
erozygous for the c.509_510delGA frameshift mutation,
was diagnosed with synchronous bilateral disease at the
age of 63 years. She presented with bilateral invasive
lobular breast cancer, with an additional invasive ductal
component in one tumor; both cancers were of stage 1
(T1N0M0 and T1N0M0) and had positive estrogen and
progesterone receptor status. Again, there was no family
history of breast cancer, but her father suffered from a
stomach cancer. None of the ten patients who carried a
mutation in BRCA1 or BRCA2 was also a carrier of trun-
cating PALB2 mutation; if we consider the frequency of
PALB2 heterozygotes in BRCA1/2-negative German
bilateral breast cancer cases, this estimate will approach to
2/148 (1.4%).
The investigation of 45 (4.4%) Russian patients with
bilateral breast cancer revealed another two deleterious
mutations. One woman carried the c.1240C[T (p.R414X)
allele in exon 4; this mutation has been previously
described in a European family with pancreatic cancer
[20]. This patient developed ﬁrst disease at age 66 (IDC,
T2N1M0, ER?/PR?) and the contralateral tumor at age 70
(Paget’s carcinoma, T1N0M0, ER-/PR?). She reported
that her mother was also affected by breast cancer. The
second patient had a newly identiﬁed mutation,
c.2761C[T (p.Q921X). She was diagnosed with syn-
chronous bilateral breast cancer at age 48 (both tumors:
IDC, T4N0M0, ER?/PR-); her mother suffered from
breast cancer, and her maternal grandfather was diagnosed
with stomach cancer.
Six missense substitutions were identiﬁed besides the
four truncating mutations (Table 2). The variants p.Q559R,
p.E672Q, p.V932M, p.L939W and p.G998E are known to
be relatively common both in breast cancer patients and in
healthy controls [8]. Bioinformatic analysis using SIFT and
PolyPhen-2 classiﬁed p.Q559R and p.V932M as benign,
whereas p.E672Q, p.L939W and p.G998E were predicted
as probably damaging by one or both of these software
tools [8]. The new missense variant, p.K18R, was observed
in two bilateral breast cancer cases from this study. It
Table 2 PALB2 coding sequence alterations in 158 German and 45 Russian patients with bilateral breast cancer
Exon Nucleotide
variation
Amino acid change Allelic counts in German
patients (relative fraction)
Allelic counts in Russian
patients (relative fraction)
Reference
2 53A[G K18R 2 (0.01) – This study
4 509_510delGA Frameshift mutation
(R170X)
1( \0.01) – Dansonka-
Mieszkowska
et al. [21]
807T[C G269G 1 (\0.01) – This study
1240C[T Nonsense mutation
(R414X)
– 1 (0.01) Slater et al. [20]
1470C[T P490P – 1 (0.01) rs45612837
1572A[G S524S 1 (\0.01) – rs45472400
1633G[T Nonsense mutation
(E545X)
1( \0.01) – This study
1676A[G Q559R 18 (0.06) 6 (0.06) rs152451
5 2014G[C E672Q 11 (0.03) 1 (0.01) rs45532440
8 2761C[T Nonsense mutation
(Q921X)
– 1 (0.01) This study
2794G[A V932 M 2 (0.01) 3 (0.03) rs45624036
2816T[G L939 W 1 (\0.01) – rs45478192
9 2993G[A G998E 9 (0.03) 1 (0.01) rs45551636
3300T[G T1100T 7 (0.02) 1 (0.01) rs45516100
13 3495G[A S1165S 1 (\0.01) – rs45439097
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123resides in a putative coiled-coil region of unknown func-
tional importance and is predicted by PolyPhen-2 to be
probably damaging. Large-scale case–control comparisons
as well as functional studies will be useful to identify any
possible disease risks associated with these variants.
While the data indicate that PALB2 mutations are rela-
tively uncommon in German and Russian populations, it
may be noteworthy that the rate of mutation carriers
appears somewhat higher in our series of bilateral breast
cancer (2%) than in most published series of familial breast
cancer from other populations (Table 1). This would be in
line with the assumption that patients with bilateral disease
constitute a subgroup where the detection of rare at-risk
alleles is particularly effective [28–31].
In summary, truncating PALB2 heterozygous mutations
have been identiﬁed in 4/203 (2%) breast cancer patients
with bilateral disease. We conclude that PALB2 mutations
contribute to a small fraction of bilateral breast cancer in
Germany and Russia. The observation that two of the four
mutations identiﬁed in our study are recurrent [20, 21] may
provide a rationale for mutation-speciﬁc screening efforts
in extended series of Eastern and Central European cancer
patients.
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